YahooOctober 23, 2026 at 11:02 PM NY3 Days Ago
Vertex Highlights Kidney Pipeline as Povetacicept Cuts Proteinuria 52% in Phase III
Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD. Chief Executive Officer and President Reshm
What This Story Means
Claude is explaining the story in plain words…
Read the Full Story at the Source
The summary here comes from the news provider; the rest of the article lives on the publisher's site: Yahoo
